Business Wire

TX-PLANVIEW

10.5.2021 15:02:12 CEST | Business Wire | Press release

Share
Planview Names Razat Gaurav as Chief Executive Officer

Planview, a global leader in Portfolio Management and Work Management, today announced the appointment of Razat Gaurav as Chief Executive Officer, effective immediately. Gaurav, who is also joining the Company’s Board of Directors, succeeds Greg Gilmore, who is retiring and will continue to serve on the Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005500/en/

With more than 20 years of experience in the enterprise software space, Gaurav brings proven leadership in scaling and growing businesses on a global basis. Most recently, Gaurav served as CEO of LLamasoft, where he was instrumental in driving an expanded product vision for AI based supply chain design and decision making. This vision, combined with a purpose-driven culture, enabled the company to more than double its revenue in three years and resulted in a successful $1.5 billion acquisition by Coupa in November 2020. Earlier in his career, Gaurav held leadership positions at Blue Yonder, i2 Technologies, and Ernst & Young’s management consulting practice. He also served on the Board of Directors of Sparta Systems (since acquired by Honeywell) and LLamasoft.

“Enterprises today are grappling with massive change and a surge in digital transformation initiatives – and the way teams work to turn strategy into outcomes has to evolve,” said Gaurav. “Planview has a rich history of technology innovation and industry leadership, as well as a proven track record of partnering with customers to transform their enterprises to meet the demands of our changing environment. I’m pleased to join Planview at an exciting time in the company’s growth trajectory and look forward to working with the team to reimagine the future of digital transformation in the enterprise.”

Gaurav’s appointment marks the next step for Planview as it looks to further accelerate its growth. Most recently, Planview acquired Clarizen and Changepoint , advancing the Company’s leadership in Portfolio Management and Work Management, and creating an unmatched community of Agile leaders, PMOs, PPM, and Professional Services Automation (PSA) practitioners. In December 2020, the company was acquired by private equity firms TPG and TA Associates for $1.6 billion .

“I have had the privilege of knowing Razat for several years and have seen firsthand his ability to build technology businesses that create differentiated value for their customers. His track record of driving growth through innovation and company culture makes him a perfect fit for Planview,” said Nehal Raj, Partner at TPG Capital. On behalf of the Board, I want to thank Greg for his leadership and stewardship of Planview for more than 25 years. We wish him the best in his retirement and appreciate his continued service on the board.”

“Under Greg's leadership, Planview has established itself as an industry leader and trusted partner to its customers,” said Ashu Agrawal, a Managing Director at TA Associates. “Looking ahead, we are confident that Razat brings the ideal combination of digital transformation expertise and experience successfully scaling enterprise software businesses to lead Planview through its next chapter. We’re pleased to welcome him aboard.”

“It has been an honor and a privilege to help lead Planview for the last 25 years, and to work alongside such extraordinary colleagues, customers, and partners,” said Gilmore. “I’m proud of the accomplishments and results we have delivered as a company, and believe that Planview is well positioned for exceptional success in the years to come.”

About Planview

Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1,000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: www.planview.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye